arrow
M

Maurizio Facheris

AbbVie
H指数:30
被引数:6,469

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Improvement in Motor Consistency and Stability with Foslevodopa/Foscarbidopa in Advanced Parkinson’s Disease: Post Hoc Analysis of Two Phase 3 Clinical Trials

在晚期帕金森病中使用Foslevodopa/Foscarbidopa改善运动一致性和稳定性:两项III期临床试验的回顾性分析

2025-10-040
OA
Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson's Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study (vol 12, 1937, 2023)

连续皮下注射Foslevodopa/Foscarbidopa治疗帕金森氏病: 安全性和有效性来自12个月,单臂,开放标签,3期研究的结果 (第12卷,1937,2023)

2023-10-100
OAAI
Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson's Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study (Aug, 10.1007/s40120-023-00533-1, 2023)

连续皮下注射Foslevodopa/Foscarbidopa治疗帕金森病: 一项为期12个月,单臂,开放标签,3期研究的安全性和有效性结果 (8月,10.1007/s40120-023-00533-1,2023)

2023-08-2637
OAAI
Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study
2020-01-0186
OAAI
Biometric monitoring devices for assessing end points in clinical trials: developing an ecosystem
2017-09-2230
OAAI
The Cooperative Health Research in South Tyrol (CHRIS) study: rationale, objectives, and preliminary results
2015-11-0572
OAAI